' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study.
Koethe, D; Juelicher, A; Nolden, BM; Braunwarth, WD; Klosterkötter, J; Niklewski, G; Wodarz, N; Klatt, J; Burtscheidt, W; Gaebel, W; Markus Leweke, F;
Alcohol Clin Exp Res. 2007; 31(7):1188-1194
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Niklewski Günter

Abstract

Alcohol withdrawal syndrome (AWS) is a serious complication of alcohol dependence and often requires intensive medical treatment. Antiepileptic drugs (AEDs) have been shown to be as efficacious in the treatment of AWS in several controlled trials as benzodiazepines and superior to placebo in relieving alcohol withdrawal symptoms. Oxcarbazepine (OXC), a newer anticonvulsive drug, has a favorable safety profile over carbamazepine (CBZ) and other older AEDs due to its excellent efficacy and better side-effect profile.


Useful keywords (using NLM MeSH Indexing)

Adult

Alcoholism/psychology

Alcoholism/rehabilitation

Behavior, Addictive/drug therapy

Behavior, Addictive/psychology

Carbamazepine/adverse effects

Carbamazepine/analogs*

derivatives*

Carbamazepine/therapeutic use

Double-Blind Method

Ethanol/adverse effects*

Female

Humans

Male

Middle Aged

Pilot Projects

Substance Withdrawal Syndrome/drug therapy*

Treatment Outcome


Find related publications in this database (Keywords)

alcohol withdrawal
oxcarbazepine
clomethiazol
double-blind
randomized
controlled trial
addiction